Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
BMS, Enterome form microbiome pact
by Lisa M. Jarvis
November 21, 2016
| A version of this story appeared in
Volume 94, Issue 46
Bristol-Myers Squibb will pay Enterome $15 million up front as part of a pact to develop microbiome-derived biomarkers and therapeutics for cancer. The partners will also look for microbiome-derived biomarkers that could indicate whether a patient will benefit from BMS’s immuno-oncology treatments. Given growing evidence that the gut microbiome is involved in how the body responds or grows resistant to cancer immunotherapies, the companies hope to find new targets and therapies that could boost the efficacy of oncology drugs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X